A considerable change hit Denmark’s business this September when new Novo Nordisk CEO Mike Doustdar announced that 9,000 jobs would be cut globally.
“Our markets are transforming, especially in the obesity segment, as it has become increasingly competitive and driven by consumer demand,” stated CEO Mike Doustdar.
This is the biggest layoff in Danish company history, and the news came just a month after Doustdar took charge.
It marks a significant shift for Novo Nordisk, which had been hiring rapidly during the weight-loss drug boom after launching Ozempic and Wegovy.
Financial Impact
Novo Nordisk expects to save $1.25 billion yearly from 2026 onward because of these job cuts. They say the savings will go back into research on new diabetes and obesity drugs.
However, laying off so many people costs money up front, with one-time costs of about 9 billion Danish kroner.
Because of these costs, Novo Nordisk had to lower its profit forecast for 2025 from as much as 27% growth to 4% and 10%. Most job losses will be in Denmark, and the rest in Novo’s 80 global offices.
Market Pressures
Novo once led the obesity-drug market with no rivals, especially after Wegovy’s 2021 U.S. approval. But competition has heated up, Eli Lilly’s Zepbound is now winning market share, and cheaper compounded versions of GLP-1 drugs have eroded Novo’s dominance.
“The obesity market was miscalculated. It’s far more consumer-driven than expected, and Novo expanded organizational complexity too rapidly,” commented Lukas Leu, shareholder and portfolio manager.
Although the global GLP-1 drug market is expected to soar to nearly $49 billion by 2030, Novo’s share is shrinking.
Leadership Crisis
These layoffs come after longtime CEO Lars Fruergaard Jorgensen was pushed out, following a 50% drop in Novo’s stock price.
Mike Doustdar, the first non-Danish CEO in the company’s century-long history, was promoted after running international sales, where he previously doubled sales to 112 billion Danish kroner in 2024. The board wanted someone who could act quickly against competitors and lead a significant turnaround.
“At times, the most challenging choices are the ones that pave the way for the future we are constructing. I believe this is the appropriate step for the long-term prosperity of Novo Nordisk,” Doustdar wrote on LinkedIn.
Restructuring Signals a New Direction
By laying off 9,000 people, Novo Nordisk admitted it had become too large and slow to keep up with its faster rivals.
Doustdar said, “Our markets are evolving, particularly in obesity, as it has become more competitive and consumer-driven.”
In other words, Novo once thought it could dominate forever, but the market changed faster than the company.
Danish Impact
Losing 5,000 jobs in Denmark is a massive blow for the country. Novo Nordisk was so big that it was worth more than the Danish economy at its $650 billion peak.
Their headquarters are significant economic and employment centers, especially for skilled workers.
Now, government officials must figure out how to help thousands of high-skilled professionals transition and cope with the loss of tax revenue.
Personal Stories
Employees were told through company-wide messages and will learn specific details over the coming months.
Many workers, confident from years of job growth, feel stunned and betrayed. Some had even moved their families internationally to join Novo during its growth years, only to face layoffs now.
The cuts range from research scientists to manufacturing staff, disrupting hundreds of families’ plans.
Eli Lilly’s Advantage
Eli Lilly has pulled ahead by releasing tirzepatide, which can deliver up to 27% weight loss, compared to Novo’s 15%, in clinical trials and expanding its offerings.
“Investors are starting to talk about Lilly on their own cue, rather than in the context of Novo,” stated Goldman Sachs analysts.
Lilly’s expanded drug lineup, including easy-to-take pills and drugs that preserve muscle as people lose weight, further secures its lead.
Supply Chain Failures
Novo Nordisk couldn’t keep up with demand. Drug shortages, especially for popular pills like Ozempic, sent many patients elsewhere or to cheaper, compounded pharmacy versions.
Regulators warned that shortages might last through 2024. Because of this, doctors and patients formed new habits, switching to rivals or risky alternatives, sometimes from unregulated online sellers, damaging Novo’s reputation and market share.
The Compounding Threat
Novo’s production failures let a whole new $80 billion compounding industry flourish, one that millions used for more affordable drugs.
Even after the FDA banned most compounded GLP-1 medications in 2025, the damage was done; patients and doctors had gotten used to these cheaper alternatives, and telehealth clinics had set up quick distribution networks for personalized medicine.
Internal Reckoning
To compete, CEO Doustdar is changing Novo’s culture fast. He wants a “performance-based culture,” ending the flexible, employee-friendly work norms of the past.
Full-time office work resumes in January 2026. Middle managers and support staff face the deepest cuts as Doustdar streamlines layers built up during rapid expansion.
“This means instilling an increased performance-based culture, deploying our resources ever more effectively, and prioritizing investment where it will have the most impact, behind our leading therapy areas,” Doustdar said.
R&D Pressure
Novo plans to invest $1.25 billion in savings into research and drug development, hoping to catch up to rivals.
However, its latest new medicine didn’t outperform Eli Lilly’s drugs. The company is also working on tablets and new treatments, which will take years.
Meanwhile, investors are growing impatient for a quick breakthrough and precise results.
Manufacturing Expansion
Even as jobs are being cut, Novo is still investing in new manufacturing plants and automation, spending $9 billion to fix production bottlenecks.
This includes a significant purchase of Catalent facilities in the U.S. and Europe, and a $6.4 billion investment in Brazil.
These changes are meant to keep up with demand and to never fall behind on supply again.
Stock Recovery
Investors welcomed the news, with Novo’s shares rising about 2% after the announcement. However, the company’s overall market value has dropped from $650 billion to $181 billion in the past year.
Analysts believe another profit warning is likely later this year and say these significant workforce changes show Novo knows it can’t go back to business as usual.
Future Implications
Novo’s new chapter is a warning for the drug industry: past success doesn’t guarantee future wins, especially in a rapidly changing market that rewards innovation, lower prices, and reliable supplies.
More industry shakeups could follow if Doustdar’s cost-cutting and focus efforts don’t pay off.
With anti-obesity drug sales expected to hit over $55 billion in a decade, the competition for market leadership will only get more intense.
Regulatory Shifts
The FDA’s ban on compounded GLP-1 drugs in May 2025 helped Novo, but it can’t erase the impact of years where patients found easy, cheap alternatives.
At the same time, new generic drugs and changing government insurance rules mean Novo must keep innovating if it wants to stay ahead, especially as more competitors enter the market.
Industry Ripple Effects
Novo’s restructuring will flood the market with skilled scientists and managers, allowing rivals to hire experienced talent and quickly grow their research teams.
Smaller drug companies might benefit from picking up these laid-off specialists, while the changes demonstrate how quickly today’s market can erase even a giant’s lead if it doesn’t keep up.
Public Reaction
The scale of the layoffs shocked many in Denmark, where Novo was a point of national pride. Workers and their families are reeling.
Some patient groups now worry about drug prices and access, despite Novo promising to expand manufacturing.
Social media is full of debate as Denmark faces the most significant job cuts in its corporate history.
Historical Precedent
Experts compare Novo’s struggle to past corporate stumbles, like Kodak missing the switch to digital cameras, or big pharma companies forced to cut jobs after patent losses.
However, Novo is taking action while its products are still in demand, hoping to avoid the damage other companies have suffered when they waited too long to adapt.
Novo’s New Reality
Novo Nordisk’s layoff decision is more than a financial move; it’s also a clear sign that in today’s fast-changing drug market, even the most prominent companies can lose their lead if they aren’t nimble.
As CEO Doustdar pushes significant changes, only time will tell if these tough steps will restore Novo’s reputation and market share.
The fight for dominance in weight-loss and diabetes drugs is just beginning, and September 10, 2025, will be remembered as the day Novo realized it must change to survive.